Justin M. Watts, MD

Justin Watts, MD, discusses key findings from a study of olutasidenib in patients with IDH1-mutated myelodysplastic syndrome.

In an interview with Targeted Oncology, Justin Watts, MD spoke about the long-term durability findings with olutasidenib and the next steps for IDH inhibitors in AML.

In an interview with Targeted Oncology, Justin Watts, MD, discussed the outcomes of a trial of the IDH1 inhibitor olutasidenib in patients with myelodysplastic syndrome.

Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.